Evidence supports use of TAVI for patients with severe, symptomatic aortic stenosis

Growing evidence supports the use of transcatheter aortic valve implantation (TAVI) for patients with severe, symptomatic aortic stenosis in the intermediate risk category in the intermediate risk category, says Edwards Lifesciences. Findings from the PARTNER II randomised trial published in the New England Journal of Medicine showed that TAVI, using the Edwards SAPIEN 3 valve, has outcomes similar to surgery and even superior with transfemoral access in the intermediate-risk patient population. Additionally, a clinical practice guideline based on three systematic reviews was published in the British Medical Journal and recommended TAVI for patients at low to intermediate surgical risk. There